1196 Streamlining T cell engager development with a diverse panel of fully human CD3-binding antibodies, bispecific engineering technology, and an integrated discovery engine

<h3>Background</h3> CD3 T cell engagers have the potential to be a cornerstone of immuno-oncology. However, a limited pool of CD3-binding antibodies and technological challenges in engineering bispecifics have hindered development. Discovering effective T cell engagers requires two target-binding arms — a CD3 arm that fine-tunes T cell activation and a tumor arm with high specificity for cancer cells — optimized as a whole to work in concert with each other. Beginning with diverse panels of antibodies increases the probability of finding appropriately potent and developable T cell engagers and reduces the need for downstream engineering. <h3>Methods</h3> We used microfluidic technology to screen more than 3.5 million single cells from humanized mice and identified &gt;200 CD3-specific antibodies. Using high-throughput assays, we determined affinity for CD3εδ and CD3εγ, cross-reactivity to human and cyno primary T cells, CD3 binding kinetics, and epitope bins. We assessed T cell activation by measuring CD25 and CD69 expression by flow cytometry. We then used our bispecific engineering platform, OrthoMab^TM, to generate a proof-of-concept panel of CD3 x EGFR bispecific antibodies. Developability properties were assessed, including hydrophobicity (aHIC), self-association (AC-SINS), polyspecificity (BVP-ELISA), stability (nanoDSF), and aggregation (aSEC). CD3 T cell engager potencies were measured using an NFAT reporter T cell activation assay and an xCELLigence tumor cell killing assay, and cytokine release was assessed by FLEXMAP CD. <h3>Results</h3> We identified hundreds of fully human CD3-specific antibodies that are diverse, developable, and validated. The antibodies displayed a wide range of CD3 binding affinities (K_D ~1 nM to 1 μM), binding kinetics, and T cell activation potencies (EC₅₀ ~6 to 190 nM). Data on this novel panel includes epitope binning, which revealed human and cyno CD3-binders that are distinct from previously described cross-reactive antibodies. The antibodies were assessed using a range of biophysical assays and have favorable developability properties. In an expanded proof-of-concept study, we used OrthoMab^TM to generate a panel of CD3 x EGFR bispecific antibodies. The resulting bispecifics had favorable developability properties, and displayed a wide range of antigen-dependent T cell activation (EC₅₀ ~2 pM to 2 nM) and tumor cell killing potencies (EC₅₀ ~0.01 to 1 nM). From this panel, we identified potent T cell engagers that achieved &gt;90% tumor cell killing with low levels of cytokine release. <h3>Conclusions</h3> By integrating our panel of CD3-binding antibodies with our bispecific engineering and high-throughput antibody assessment capabilities, we identified developable CD3 T cell engagers with potent tumor cell-killing activity and minimal cytokine release.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.